anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A progestogen sustained-release suppositories device has a basal body for slowly releasing the progestogen mixture. The sustained-release basal body is supported by the plastic backbone inside the basal body which is formed by complete mixing of the progestogen components and silica gel, with two opening wings, on which an opening plane is left, forming the round ligament part. The basal body has a round and smooth surface, and its rear forms the round ligament part. The utility model can effectively control the generation and release of follicle stimulating hormone and luteinizing hormone, realize the control on oestrus of domestic animals at the same phase, with the effect of preventing the conglutination and reducing the inflammation. The utility model has better release effect, with more smooth and comfortable structure. The utility model is with simple making method and can bring considerable economic benefit to the animal husbandry.
Obesity and its associated comorbidities constitute a serious and growing public health burden. Fractures affect a substantial proportion of people with obesity and result from reduced bone strength relative to increased mechanical loading, together with an increased risk of falls. Factors contributing to fractures in people with obesity include adverse effects of adipose tissue on bone and muscle and, in many people, the coexistence of type 2 diabetes. Strategies to reduce weight include calorie-restricted diets, exercise, bariatric surgery, and pharmacological interventions with GLP-1 receptor agonists. However, although weight loss in people with obesity has many health benefits, it can also have adverse skeletal effects, with increased bone loss and fracture risk. Priorities for future research include the development of effective approaches to reduce fracture risk in people with obesity and the investigation of the effects of GLP-1 receptor agonists on bone loss resulting from weight reduction.
Despite the high mortality associated with sepsis, effective and targeted treatments remain scarce. The use of conventional antibiotics such as TIENAM (imipenem and cilastatin sodium for injection, TIE) is challenging because of the increasing bacterial resistance, which diminishes their efficacy and leads to adverse effects. Our previous studies demonstrated that ulinastatin (UTI) exerts a therapeutic impact on sepsis by reducing systemic inflammation and modulating immune responses. In this study, we examined the possibility of administering UTI and TIE after inducing sepsis in a mouse model using cecal ligation and puncture (CLP). We assessed the rates of survival, levels of inflammatory cytokines, the extent of tissue damage, populations of immune cells, microbiota in ascites, and important signaling pathways. The combination of UTI and TIE significantly improved survival rates and reduced inflammation and bacterial load in septic mice, indicating potent antimicrobial properties. Notably, the survival rates of UTI+TIE-treated mice increased from 10 % to 75 % within 168 h compared to those of mice that were subjected to CLP. The dual treatment successfully regulated the levels of inflammatory indicators (interleukin [IL]-6, IL-1β, and tumor necrosis factor [TNF]-α) and immune cell numbers by reducing B cells, natural killer cells, and TNFR2+ Treg cells and increasing CD8+ T cells. Additionally, the combination of UTI and TIE alleviated tissue damage, reduced bacterial load in the peritoneal cavity, and suppressed the NF-κB signaling pathway. Our findings indicate that UTI and TIE combination therapy can significantly enhance sepsis outcomes by reducing inflammation and boosting the immune system. The results offer a promising therapeutic approach for future sepsis treatment.
General: After intramuscular injection, iron dextran is absorbed from the injection site into the capillaries and the lymphatic system. Circulating iron dextran is removed from the plasma by cells of the reticuloendothelial system, which split the complex into its components of iron and dextran. The iron is immediately bound to the available protein moieties to form hemosiderin or ferritin, the physiological forms of iron, or to a lesser extent to transferrin. This iron which is subject to physiological control replenishes hemoglobin and depleted iron stores.

Dextran, a polyglucose, is either metabolized or excreted. Negligible amounts of iron are lost via the urinary or alimentary pathways after administration of iron dextran.

The major portion of intramuscular injections of iron dextran is absorbed within 72 hours; most of the remaining iron is absorbed over the ensuing 3 to 4 weeks.

Various studies involving intravenously administered 59Fe iron dextran to iron deficient subjects, some of whom had coexisting diseases, have yielded half-life values ranging from 5 hours to more than 20 hours. The 5-hour value was determined for 59Fe iron dextran from a study that used laboratory methods to separate the circulating 59Fe iron dextran from the transferrin-bound 59Fe. The 20-hour value reflects a half-life determined by measuring total 59Fe, both circulating and bound. It should be understood that these half-life values do not represent clearance of iron from the body. Iron is not easily eliminated from the body and accumulation of iron can be toxic.

In vitro studies have shown that removal of iron dextran by dialysis is negligible.1,2 Six different dialyzer membranes were investigated (polysulfone, cuprophane, cellulose acetate, cellulose triacetate, polymethylmethacrylate and polyacrylonitrile), including those considered high efficiency and high flux.
A randomized clinical trial was conducted in the Institute of Translational Nutrigenetics and Nutrigenomics, Department of Molecular Biology in Medicine, Health Sciences Center, at the University of Guadalajara, Guadalajara, Jalisco, Mexico, from February of 2018 to February of 2019. All participants were recruited through flyers and social media invitations. Sample size was determined according to the mean difference formula for clinical trials. To achieve a statistical power of 80% and an alpha of 5%, a sample size of 13 participants in each study group was required. However, 37 obese individuals who met the selection criteria were randomized in exercise-diet group or diet-group. Blood sample, height and weight were measured after 8-12 hour fast and wearing light clothes. The participants in the exercise-diet group were cited in the Respiratory Unit of the University of Guadalajara with the indication of not consuming caffeine, tobacco or energy drinks 24 hours before the test, and not having eaten food at least two hours before the Astrand-rhyming Test. This study was approved by the Ethics and Biosafety Committee of the Health Sciences Center, University of Guadalajara (registry number CUCS/CINV/0476/18). The procedures were in accordance with this institution's guidelines and all the participants signed a written consent-informed.
Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.
Morphine 8 mg/day on weeks one and two. Morphine 16 mg/day on week three.
BACKGROUND: Minimally invasive surgery (MIS) in medial displacement calcaneus osteotomy (MDCO) has been proposed for surgical correction of adult-acquired flat foot deformity (AAFD) to reduce complications of open approaches. The aim of our study is to systematically analyze complications and the clinical and radiological results of MIS- MDCO.
METHODS: A systematic review of the English literature was performed on 30th October 2023. Randomized controlled trials and non-randomized trials, cohort studies, case-control studies and case series concerning surgical correction of AAFD with MIS-MDCO and with at least 15 patients were included. Case reports, technical notes, animal or cadaveric studies were excluded. The quality and risk of bias of the studies included were evaluated using GRADE and MINORS systems. Complications rate, clinical and radiological results were inferred from the studies included.
RESULTS: Nine articles were included. A total of 501 cases treated with MIS-MDCO were analysed with a mean follow-up of 11.9 ± 5.1 months. The reported wound infection rate was about 3% and sural neuropathy was rated about 1%. Only 4% of the cases required removal of the screw for pain. In the comparative studies (MIS versus Open MDCO), comparable clinical results but with significant differences (P < 0.001) in infection rates (1% versus 14%) and sural neuropathy (2% versus 1%) were observed.
CONCLUSION: AAFD correction performed with MIS-MDCO, with the limitation of a poor quality and high risk of bias of the included studies, seems to provide good clinical results and high subjective satisfaction with a lower complication rate compared to open approach. Further high-quality long-term comparative studies could better clarify complications and clinical and radiological outcomes of the MIS technique in the treatment of AAFD.
LEVEL OF EVIDENCE: Level IV.
The recommended dose of TIBSOVO is 500 mg taken orally once daily until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.

Administer TIBSOVO with or without food. Do not administer TIBSOVO with a high-fat meal because of an increase in ivosidenib concentration [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. Do not split or crush TIBSOVO tablets. Administer TIBSOVO tablets orally about the same time each day. If a dose of TIBSOVO is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of TIBSOVO is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours.

Patients with the Comorbidities of Severe Renal or Severe Hepatic Impairment

Treatment with TIBSOVO has not been studied in patients with pre-existing severe renal or hepatic impairment. For patients with pre-existing severe renal or hepatic impairment, consider the risks and potential benefits before initiating treatment with TIBSOVO [see Use in Specific Populations (8.6, 8.7)].
The invention discloses an anti-CA 199 antibody and application thereof, wherein the heavy chain amino acid sequence of the antibody is shown as SEQ ID NO.1, and the light chain amino acid sequence is shown as SEQ ID NO. 2. The amino acid sequence of the variable region of the heavy chain of the antibody is shown as SEQ ID NO.3, and the amino acid sequence of the variable region of the light chain is shown as SEQ ID NO. 4. The variable region sequences of the CDR1, the CDR2 and the CDR3 of the antibody heavy chain are shown in SEQ ID NO. 5-7, and the variable region sequences of the CDR1, the CDR2 and the CDR3 of the antibody light chain are shown in SEQ ID NO. 8-10. A nucleic acid molecule encoding said anti-CA 199 antibody. The antibody provided by the invention has high activity and is stable among antibody batches. The invention has important significance for further realizing stable expression and large-scale production of the anti-CA 199 antibody.
The experimental group, in addition to following the standard guidelines, undergoes two brief therapeutic sessions using the Calgary Family Intervention Model. Each session lasts approximately 20 minutes. Both groups complete three questionnaires during the study period. Furthermore, after the study concludes, the experimental group participates in an interview lasting approximately 15 minutes before returning home.
Tumors with pathogenic DICER1 mutation are rare and encompass sporadic or hereditary benign, intermediate and malignant tumors. DICER1-associated sarcomas are heterogeneous; however, the prototypical ones in the GYN-tract include embryonal rhabdomyosarcoma, adenosarcoma and moderately to poorly differentiated Sertoli-Leydig tumor. In this report, we present three unique uterine sarcomas with DICER1 mutation and remarkable diffuse round/spindle cell morphology. The tumors occurred in cervix (n = 1), and uterine corpus (n = 2). The patient ages were 30, 37 and 59 years with tumor size of 8.8, 10 and 8.6 cm, respectively. Morphologically all three tumors were characterized by distinct spindle/round cell morphology and various amounts of neuroectodermal differentiation (yolk sac-like tubules, blastomatous areas and rosette formation). Other morphologic features of DICER1-sarcoma reported in the literature including cambium layer, focal or diffuse anaplasia, solid and cystic architecture, and chondroid/osteoid areas were absent. All three sarcomas were positive for SALL4 and had variable neuroendocrine marker expression. Whole genome methylation analysis was performed on one of the uterine sarcomas, which clustered the tumor with embryonal tumor with multilayered rosettes. Follow up information was available on all three cases. Two patients were alive with no evidence of disease 13 and 14 months post operation, while one patient had imaging evidence of local recurrence 4 months post operation. In summary, we describe three unique DICER1-sarcomas and expand the phenotypic spectrum of this emerging entity, particularly with GYN-tract origin.
This study will enroll individuals with autism and their family members from autism-related medical, nongovernmental organizations, and general educational settings, where from elementary schools to colleges, in Taiwan. For patients and their family, the investigators will enroll total 2000 adult individuals with autism and their family members for the questionnaire survey. The needs of assessment and care, and intervention models in autism will be examined using the Chinese version of Camberwell Assessment of Need, autistic traits assessment, emotional difficulty questionnaire, quality of life and Self-administered questionnaire with different versions for stakeholders. The guides for parents and clinicians on autism will be discussed with the patient and family representatives and developed by different autism stakeholders, experts, and scholars based on regular research meetings. Quantitative analyses will be conducted to understand the need and difficulty of care and interventions in autism across different developmental stage.

The investigators anticipate to find differences in care needs by personal characteristics. The survey of the care needs of autism will provide family members, medical and nursing personnel, and related caregivers more information about understanding their care requirements. These results will help the government for the formulation of policies related to early treatment and long-term care. Finally, the guides for parents and clinician on autism would be suggested references.
Legionellers' desease accounts for 1-8 % of cases of severe community-acquired pneumonia (CAP). Legionella spp. Is the causative organism that can result in respiratory failure, multi-organ dysfunction, sepsis, and death. Therefore, rapid diagnosis and efficient treatment are crucial. We report the clinical and microbiology study of a patient with community-acquired pneumonia caused by Legionella pneumophila, with fatal outcome. After death, the strain causing the infection was identified as Legionella pneumophila serogroup 1, Olda OLDA phenotype and sequence-type 1. This is the first reported case of septic shock and death associated with an isolate of these characteristics.
The invention relates to novel compounds which are both phosphodiesterase 4 (PDE4) enzyme inhibitors and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. M3 Binging assay: CHO-KI clone cells expressing the human M3- receptor (Swissprot P20309) were harvested in Ca++/Mg++free phosphate-buffered saline and collected by centrifugation at 1500 rpm for 3 min. The pellets were resuspended in ice cold buffer A (15 mM Tris-HCI pH 7.4, 2 mM MgCI2, 0.3 mM EDTA, 1 mM EGTA) and homogenized by a PBI politron (setting 5 for 15 s). The crude membrane fraction was collected by two consecutive centrifugation steps at 40000 g for 20 min at 4°C, separated by a washing step in buffer A. The pellets obtained were finally resuspended in buffer B (75 mM Tris HCI pH 7.4, 12.5mM MgCI2, 0.3 mM EDTA, 1 mM EGTA, 250 mM sucrose), and aliquots were stored at - 80°C. The day of experiment, frozen membranes were resuspended in buffer C (50 mM Tris-HCI pH 7.4, 2.5 mM MgCb, 1 mM EDTA). The non selective muscarinic radio ligand [3H]-N-methyl scopolamine(Mol.Pharmacol.45:899-907) was used to label the M3 binding sites. Binding experiments were performed in duplicate (ten point concentrations curves) in 96 well plates at radioligand concentration of 0.1-0.3 nM. The non specific binding was determined in the presence of cold N-methyl scopolamine 10 uM. Samples (final volume 0.75 mL) were incubated at room temperature for 90 min. The reaction was terminated by rapid filtration through GF/B Unifilter plates and two washes (0.75 mL) with cold buffer C using a Packard Filtermate Harvester. Radioactivity on the filters was measured by a microplate scintillation counter TriCarb 2500 (PerkinElmer). Representative compounds of the invention, when tested in one of the above reported protocols, displayed an IC50 lower than 100 nM. Representative compounds of the invention displayed an IC50 lower than 100 nM in both PDE4 cell free and M3 binding assays.
A new DLBCL cohort (DLBCL-2) in order to evaluate intermittent schedules of CC-122 (5 continuous days out of 7 days per week \[5/7 days\] and/or 21 continuous days out of 28 days per cycle \[21/28 days\]). Doses to be explored include 4 mg and 5 mg on an intermittent schedule using the 3+3 design described in Part A in order to establish an MTD for the intermittent dosing schedules. Following dose escalation, one or more intermittent dosing schedules may be expanded at or below the new intermittent schedule MTD in at least 20 total subjects per dosing schedule.
The articles, comprising a foamed synthetic polymer matrix contg. a number of interconnected cells, at least some of which form surface pores, are characterised by containing in the cells an additive (e.g. cosmetic, polish, cleaning agent, antimicrobial agent, deodorant) which is relatively insol. in the solid polymer, can be sepd. from the polymer and is not a medicine. The matl. can be supplied as a soln. of polymer in volatile blowing agent, contg. dissolved or dispersed additive, e.g. in an aerosol container, and used to form articles at normal temp. and press.
The invention discloses a method for diagnosing diseases based on the combination of conventional test data and a knowledge map. The overall architecture comprises a data acquisition module, a data analysis module and a data analysis module, wherein the data acquisition module is used for acquiring conventional inspection data; and the data processing module is used for cleaning the acquired data. And the model construction module is used for constructing the model by utilizing the neural network. And the model prediction module is used for inputting the sample to be tested into the neural network model to obtain a result. And the knowledge graph combination module is used for combining the result predicted by the model into the knowledge graph to acquire result related knowledge. And the result output module is used for combining the diseases identified by the model prediction module with the disease-related knowledge in the knowledge map combination module and finally outputting the disease incidence and disease symptoms. The method has the advantages that the method is based on the routine inspection data of the hospital clinical laboratory, can provide early diagnosis prompt for doctors to avoid missed diagnosis, and can help patients to prevent diseases in advance.
2-Methoxy-4-amino-5-chloroaminoethyl-N,N-(diethylamino)-benzamide of formula (I): is prepd. by reacting 2-methoxy-4-acetylamino-5-chlorobenzoic acid methyl ester with bromoethylamine hydrobromide, diethylamine and sodium methylate in propylene glycol at 20-120 degrees C for 12 hrs. The prod. is acidified with acetic acid, filtered, the amide liberated with NaOH and the prod. obtained is opt. desacetylated with 20% H2SO4. (I) normalises the gastro-duodenal activity and may be used in gastro enterology, during labour, pediatrics, neuropsychiatry, in cases of incompatibility with pharmaceuticals and to ease radioscopic investigations of the digestive system. (I) has very low toxicity.
The invention discloses a special-effect pill capable of preventing and treating gout, which is a latest product invented at present. The gout is a disease which is caused by that overmuch uric acid is difficult to excrete, the main symptom of the disease is that the joint of an affected part is red, swollen and pain, the joint of the thumb begins to pain at the beginning, and certain part of the foot joint may pain, i.e. foot, ankle, wrist and elbow joints successively pain; and the pain can last for two or three days or longer and repeatedly attacks, and patients suffer great pain. The special-effect pill capable of preventing and treating gout is composed of sanguisorba officinalis, frankincense, rhizome corydalis, myrrh, rhizome cyperi, potassium and baking soda. The special-effect pill can diminish inflammation, kill pain, dissipate blood stasis, dredge stagnancy and carry out detumescence and diuresis. The special-effect pill has special curative effect on all gout patients after being taken.
FIELD: medicine, technology for tablets production. SUBSTANCE: methods for tabletting biologically active substances are suggested including preparation of raw material - medicinal substances, fillers and shape-forming substances, reducing, sieving and sieve classification, dosing and dry mixing of prepared powders, moistening and mixing of wet mass, granulating of wet mass, drying, fragmentation and sieve calibration of dried granules, pressing of granulated mass to obtain tablets and cover them with membranes. Moreover, in addition to a filler and a shape-forming substance represented by sugar, lactose, china clay, etc., one should dose the flour of cereal grains as shape-forming substance. Moreover, raw material mass is moistened with tinctures - extracts of substances containing biologically active components prepared at desired necessary quantity of moisture. The suggested innovation enables to obtain tablets with accelerated assimilation in gastrointestinal tract. Tablets obtained due to the above-mentioned method do not stimulate mucous gastric membrane. EFFECT: higher efficiency. 10 cl
The invention provides a composition for removing dark eye circles, eye essence, and a preparation method and application thereof. The composition for removing black eye circles comprises the following components in parts by weight: 0.2 to 2 portions of rosemary extract, 0.2 to 2 portions of hydrolyzed European plums, 0.2 to 2 portions of turmeric root extract, 0.5 to 2.5 portions of capsicum frutescens fruit extract, 0.5 to 2.5 portions of glycyrrhiza glabra extract and 0.8 to 2.5 portions of cyperus rotundus root extract. Eye essence comprises the composition for removing dark eye circles. The preparation method of the eye essence comprises the following steps: and mixing the raw materials of the eye essence. Use of the composition for removing dark eye circles and eye essence for manufacturing cosmetics. The composition for removing the black eye circles and the eye essence provided by the application can effectively fade the black eye circles of the eyes and improve the skin condition around the eye sockets.